Zomig Articles
Impax buys US rights to Zomig
1 February 2012
MSD publishes strong migraine trial results
1 December 2008
AstraZeneca's Zomig nasal spray good for cluster headache
15 September 2008
Strong Ph III data for Merck & Co telcagepant
7 July 2008
UK eyes OTC triptans to treat migraine
22 August 2005
Zomig effective in adolescent migraine
4 July 2005
Zomig induces rapid relief from migraine
21 February 2005
New study confirms Zomig long-term safety
31 January 2005
Patients prefer AstraZeneca's Zomig
17 January 2005
AstraZeneca launches Zomig 5mg Rapimelt
10 January 2005
MAZE study shows inadequate use of migraine-specific medicines
13 September 2004
AstraZeneca's Zomig is top triptan in Europe
8 March 2004
Visiongain migraine and IBS market reports
1 March 2004
FDA clears AstraZeneca's Zomig nasal spray
13 October 2003
Migraine drug market to double to $5.6B in 2012
30 June 2003
AlgoRx licenses novel triptan formulation for migraine
17 February 2003
US push for generics of "gold-standard" drugs
25 February 2002
AstraZeneca's Zomig nasal spray gets first launch in Sweden
25 February 2002
"Robust" year for AstraZeneca
5 December 2001
AstraZeneca to extend Zomig-ZMT line in USA
21 September 2001
Zoladex licensed for new indication in UK
31 August 2001
AstraZeneca, GSK get Japanese OK for oral triptans
22 June 2001
AstraZeneca launches new Zomig form in USA
30 April 2001
AstraZeneca hit by slip in Losec sales
26 April 2001
AstraZeneca's fast-melt Zomig form approved in USA
15 February 2001
AstraZeneca issues sales and profits slowdown warning
8 February 2001
AstraZeneca files for Zomig nasal spray
22 November 2000
Elan's migraine drug nears US approval
4 May 2000
AstraZeneca files for first oral triptan OK in Japan
11 April 2000
Astra and Zeneca arms to merge in Japan
7 December 1999
CIMA Labs' Zomig Rapimelt backed in Europe
25 November 1999
FDA requests drug interaction data for Pfizer's Relpax
26 October 1999
AstraZeneca launches Zomig rapimelt
16 September 1999
Blow to AstraZeneca's defence of Losec
13 September 1999
CIMA's Zomig OKed in Sweden, first appro
21 July 1999
Maxalt outperforms rival triptans
1 July 1999
Rapid action of Zomig backed up by new study
4 June 1999
Zeneca's fast-dissolve Zomig filed in EU
24 February 1999
Zeneca shows confidence on Astra merger; reports good 1998 results
17 February 1999
Vanguard Medica files Miguard NDA
2 February 1999
AstraZeneca's Effect On Rest Of Pharma Sector
17 December 1998
Zeneca Receives FDA Warning Letter For Misleading Advertisments
3 December 1998
Nolvadex Approval Puts Zeneca On A High
19 November 1998
US 2nd-Qtr Rx DTC Spending Rises 25%
6 November 1998
Zeneca Pharma Sales High But Disappoints Overall
29 October 1998
Evolution In Migraine Therapy; New Triptans, And Beyond
10 September 1998
MSD Launches Maxalt In The UK
9 September 1998
Stock Commentary Europe
12 August 1998
Zeneca Profits Decline, But Underlying Growth Strong
6 August 1998
Zeneca Updates Its R&D Pipeline
6 August 1998
US Rx DTC Ad Spend Set To Beat $1 Billion Again
28 July 1998
Merck's Maxalt Approved In USA
1 July 1998
UK Pharma Leaders Outline Strategy
22 June 1998
Zomig Reimbursable In France
18 June 1998
Good Earnings Growth At Zeneca Despite Strong L
5 March 1998
Merck & Co's Rizatriptan Approved In Holland
25 February 1998
GW's Naratriptan Approved In The USA
12 February 1998
GW-SB Merger Will Create R&D Superpower
5 February 1998
Pharma Sector Boosts Zeneca 1997 Performance
28 January 1998
Zeneca Upgraded By Goldman Sachs
27 January 1998
Cima Developing Fast-Melt Zomig
22 January 1998
Migraine Market Hotting Up In The USA
20 January 1998
Broker Upgrades Zeneca On Acquisition And New Product Outlook
13 January 1998
Zeneca To Invest In Zomig Plant
6 January 1998
1997: Another Good Year For New Chemical Entities
6 January 1998
US Approval For Zomig Tablets
4 December 1997
Zeneca Allays Fears Of Near-Term Product Gap
4 December 1997
FDA Clears Zomig
27 November 1997
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
